Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Frequency Therapeutics Inc (FREQ)

Frequency Therapeutics Inc (FREQ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,420
  • Shares Outstanding, K 34,976
  • Annual Sales, $ 14,070 K
  • Annual Income, $ -84,690 K
  • 60-Month Beta 0.96
  • Price/Sales 2.76
  • Price/Cash Flow N/A
  • Price/Book 0.39
Trade FREQ with:

Options Overview Details

View History
  • Implied Volatility 171.43% ( -527.02%)
  • Historical Volatility 147.88%
  • IV Percentile 84%
  • IV Rank 12.56%
  • IV High 1,061.41% on 05/12/22
  • IV Low 43.55% on 03/07/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2,112
  • Volume Avg (30-Day) 275
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 7,168
  • Open Int (30-Day) 5,376

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.71
  • Number of Estimates 4
  • High Estimate -0.52
  • Low Estimate -0.85
  • Prior Year -0.52
  • Growth Rate Est. (year over year) -36.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0700 +3.74%
on 05/20/22
1.5750 -29.52%
on 04/25/22
-0.3800 (-25.50%)
since 04/22/22
3-Month
1.0700 +3.74%
on 05/20/22
3.0800 -63.96%
on 02/25/22
-1.8900 (-63.00%)
since 02/24/22
52-Week
1.0700 +3.74%
on 05/20/22
10.9000 -89.82%
on 06/25/21
-7.0000 (-86.31%)
since 05/24/21

Most Recent Stories

More News
Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function,...

FREQ : 1.1100 (-12.60%)
Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function,...

FREQ : 1.1100 (-12.60%)
Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function,...

FREQ : 1.1100 (-12.60%)
Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function,...

FREQ : 1.1100 (-12.60%)
Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 105.88% and 31.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the...

PSTX : 1.9900 (-4.78%)
FREQ : 1.1100 (-12.60%)
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function,...

FREQ : 1.1100 (-12.60%)
Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function,...

FREQ : 1.1100 (-12.60%)
Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function,...

FREQ : 1.1100 (-12.60%)
Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates

Frequency Therapeutics, Inc. (FREQ) delivered earnings and revenue surprises of -32.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for...

FREQ : 1.1100 (-12.60%)
Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function,...

FREQ : 1.1100 (-12.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Frequency Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company's lead product candidate, FX-322, is in clinical development and is designed to regenerate...

See More

Key Turning Points

3rd Resistance Point 1.3733
2nd Resistance Point 1.3167
1st Resistance Point 1.2133
Last Price 1.1100
1st Support Level 1.0533
2nd Support Level 0.9967
3rd Support Level 0.8933

See More

52-Week High 10.9000
Fibonacci 61.8% 7.1449
Fibonacci 50% 5.9850
Fibonacci 38.2% 4.8251
Last Price 1.1100
52-Week Low 1.0700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar